98
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Induction of Apoptosis in the Human Mast Cell Leukemia Cell Line HMC-1 by Various Antineoplastic Drugs

, , , , , & show all
Pages 509-515 | Published online: 01 Jul 2009
 

Abstract

Mast cell leukemia (MCL) is a rare disorder characterized by rapid disease progression, resistance against conventional cytoreductive drugs, and short survival. In an attempt to identify drugs that show significant antiproliferative effects on neoplastic mast cells (MC), we exposed the MCL-derived cell line HMC-1 to various cytotoxic drugs including 2-chlorodeoxyadenosine [2CdA], fludarabine and cytosine arabinoside [ARA-C]. The effects of these drugs on 3 H-thymidine incorporation, electron microscopic signs of apoptosis, and DNA fragmentation in HMC-1 cells, were analyzed. As assessed by 3 H-thymidine incorporation, all drugs produced inhibition of proliferation in HMC-1 cells with the following rank order of potency: ARA-C > doxorubicine > 2-CdA > etoposide > vincristine > fludarabine > cisplatin. Fludarabin, cisplatin, etoposide and 2-CdA also induced ladder-type fragmentation of DNA, endonuclease activity in a Tunel assay, and electron microscopic signs of apoptosis in HMC-1 cells. Together, our data show that various cytostatic drugs can induce apoptosis and inhibition of proliferation in the human MCL cell line HMC-1. Whether these drugs, alone or in combination, are also effective in patients with MCL, remains to be determined.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.